Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (171-180 of 209) with videos related to

Pageof 21
Sort By:
Archives of Dermatological Research|March 13, 2022
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VIHee J Kim, Ester Del Duca, Ana B Pavel, et al.
Journal of the American Academy of Dermatology|May 17, 2026
Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled TrialJennifer Soung, Mark G Lebwohl, Adelaide Hebert, et al.
Journal of the American Academy of Dermatology|January 13, 2021
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot studyHee J Kim, Giselle K Singer, Ester Del Duca, et al.
The Journal of Allergy and Clinical Immunology|August 29, 2015
Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewingMayte Suárez-Fariñas, Benjamin Ungar, Shinji Noda, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 5, 2021
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with DupilumabBenjamin Ungar, Jacob W Glickman, Alexandra K Golant, et al.
The Journal of Allergy and Clinical Immunology|November 27, 2015
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonismEmma Guttman-Yassky, Benjamin Ungar, Shinji Noda, et al.
Rheumatology (Oxford, England)|May 26, 2020
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
The British Journal of Dermatology|April 19, 2023
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activityA David Burden, Hervé Bachelez, Siew Eng Choon, et al.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
Rheumatology (Oxford, England)|September 22, 2021
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
Pageof 21

Showing results (171-180 of 209) with videos related to

Sort By:
Pageof 21
Archives of Dermatological Research|March 13, 2022
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VIHee J Kim, Ester Del Duca, Ana B Pavel, et al.
Journal of the American Academy of Dermatology|May 17, 2026
Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled TrialJennifer Soung, Mark G Lebwohl, Adelaide Hebert, et al.
Journal of the American Academy of Dermatology|January 13, 2021
Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot studyHee J Kim, Giselle K Singer, Ester Del Duca, et al.
The Journal of Allergy and Clinical Immunology|August 29, 2015
Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewingMayte Suárez-Fariñas, Benjamin Ungar, Shinji Noda, et al.
The Journal of Allergy and Clinical Immunology. in Practice|November 5, 2021
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with DupilumabBenjamin Ungar, Jacob W Glickman, Alexandra K Golant, et al.
The Journal of Allergy and Clinical Immunology|November 27, 2015
Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonismEmma Guttman-Yassky, Benjamin Ungar, Shinji Noda, et al.
Rheumatology (Oxford, England)|May 26, 2020
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
The British Journal of Dermatology|April 19, 2023
The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activityA David Burden, Hervé Bachelez, Siew Eng Choon, et al.
Drug Safety|October 31, 2023
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic ArthritisBruce Strober, Laura C Coates, Mark G Lebwohl, et al.
Rheumatology (Oxford, England)|September 22, 2021
Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trialsMark C Genovese, Eduardo Mysler, Tetsuya Tomita, et al.
Pageof 21